BACKGROUND: Definitive diagnosis of Alzheimer disease (AD) can be made only by histopathological examination of brain tissue, prompting the search for premortem disease biomarkers. We sought to determine if the novel brain injury biomarker, visinin-like protein 1 (VLP-1), is altered in the CSF of AD patients compared with controls, and to compare its values to the other well-studied CSF biomarkers 42-amino acid amyloid-beta peptide (Abeta(1-42)), total Tau (tTau), and hyperphosphorylated Tau (pTau). METHODS: Using ELISA, we measured concentrations of Abeta(1-42), tTau, pTau, and VLP-1 in CSF samples from 33 AD patients and 24 controls. We compared the diagnostic performance of these biomarkers using ROC curves. RESULTS: CSF VLP-1 concentrations were significantly higher in AD patients [median (interquartile range) 365 (166) ng/L] compared with controls [244 (142.5) ng/L]. Although the diagnostic performance of VLP-1 alone was comparable to that of Abeta, tTau, or pTau alone, the combination of the 4 biomarkers demonstrated better performance than each individually. VLP-1 concentrations were higher in AD subjects with APOE epsilon4/epsilon4 genotype [599 (240) ng/L] compared with epsilon3/epsilon4 [376 (127) ng/L] and epsilon3/epsilon3 [280 (115.5) ng/L] genotypes. Furthermore, VLP-1 values demonstrated a high degree of correlation with pTau (r = 0.809) and tTau (r = 0.635) but not Abeta(1-42) (r = -0.233). VLP-1 was the only biomarker that correlated with MMSE score (r = -0.384, P = 0.030). CONCLUSIONS: These results suggest that neuronal injury markers such as VLP-1 may have utility as biomarkers for AD.
BACKGROUND: Definitive diagnosis of Alzheimer disease (AD) can be made only by histopathological examination of brain tissue, prompting the search for premortem disease biomarkers. We sought to determine if the novel brain injury biomarker, visinin-like protein 1 (VLP-1), is altered in the CSF of ADpatients compared with controls, and to compare its values to the other well-studied CSF biomarkers 42-amino acid amyloid-beta peptide (Abeta(1-42)), total Tau (tTau), and hyperphosphorylated Tau (pTau). METHODS: Using ELISA, we measured concentrations of Abeta(1-42), tTau, pTau, and VLP-1 in CSF samples from 33 ADpatients and 24 controls. We compared the diagnostic performance of these biomarkers using ROC curves. RESULTS:CSFVLP-1 concentrations were significantly higher in ADpatients [median (interquartile range) 365 (166) ng/L] compared with controls [244 (142.5) ng/L]. Although the diagnostic performance of VLP-1 alone was comparable to that of Abeta, tTau, or pTau alone, the combination of the 4 biomarkers demonstrated better performance than each individually. VLP-1 concentrations were higher in AD subjects with APOE epsilon4/epsilon4 genotype [599 (240) ng/L] compared with epsilon3/epsilon4 [376 (127) ng/L] and epsilon3/epsilon3 [280 (115.5) ng/L] genotypes. Furthermore, VLP-1 values demonstrated a high degree of correlation with pTau (r = 0.809) and tTau (r = 0.635) but not Abeta(1-42) (r = -0.233). VLP-1 was the only biomarker that correlated with MMSE score (r = -0.384, P = 0.030). CONCLUSIONS: These results suggest that neuronal injury markers such as VLP-1 may have utility as biomarkers for AD.
Authors: Laure Allard; Pierre R Burkhard; Pierre Lescuyer; Jennifer A Burgess; Nadia Walter; Denis F Hochstrasser; Jean-Charles Sanchez Journal: Clin Chem Date: 2005-09-01 Impact factor: 8.327
Authors: Omar F Laterza; Vijay R Modur; Dan L Crimmins; Jitka V Olander; Yvonne Landt; Jin-Moo Lee; Jack H Ladenson Journal: Clin Chem Date: 2006-07-20 Impact factor: 8.327
Authors: E Vanmechelen; H Vanderstichele; P Davidsson; E Van Kerschaver; B Van Der Perre; M Sjögren; N Andreasen; K Blennow Journal: Neurosci Lett Date: 2000-05-05 Impact factor: 3.046
Authors: K Blennow; A Ricksten; J A Prince; A J Brookes; T Emahazion; C Wasslavik; N Bogdanovic; N Andreasen; S Båtsman; J Marcusson; K Nägga; A Wallin; B Regland; H Olofsson; C Hesse; P Davidsson; L Minthon; A Jansson; L Palmqvist; L Rymo Journal: J Neural Transm (Vienna) Date: 2000 Impact factor: 3.575
Authors: E Cavedo; S Lista; Z Khachaturian; P Aisen; P Amouyel; K Herholz; C R Jack; R Sperling; J Cummings; K Blennow; S O'Bryant; G B Frisoni; A Khachaturian; M Kivipelto; W Klunk; K Broich; S Andrieu; M Thiebaut de Schotten; J-F Mangin; A A Lammertsma; K Johnson; S Teipel; A Drzezga; A Bokde; O Colliot; H Bakardjian; H Zetterberg; B Dubois; B Vellas; L S Schneider; H Hampel Journal: J Prev Alzheimers Dis Date: 2014-12
Authors: Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2011-08 Impact factor: 10.422
Authors: Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg Journal: Mol Diagn Ther Date: 2014-04 Impact factor: 4.074